{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Merkel+Cell+Carcinoma+of+Skin&page=3", "query": { "condition": "Merkel Cell Carcinoma of Skin", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 67, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Merkel+Cell+Carcinoma+of+Skin&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Merkel+Cell+Carcinoma+of+Skin&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T21:33:37.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00079131", "title": "Oblimersen in Treating Patients With Merkel Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Neuroendocrine Carcinoma of the Skin", "Stage I Neuroendocrine Carcinoma of the Skin", "Stage II Neuroendocrine Carcinoma of the Skin", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage IV Neuroendocrine Carcinoma of the Skin" ], "interventions": [ { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079131" }, { "nct_id": "NCT00540566", "title": "Optical Biopsy of Human Skin in Conjunction With Laser Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Melanoma", "Merkel Cell Carcinoma", "Basal Cell Carcinoma", "Squamous Cell Carcinoma", "Atypical Nevi", "Congenital Nevi", "Seborrheic Keratosis", "Paget's Disease", "Dermatofibroma", "Kaposi's Sarcoma", "Port Wine Stain", "Hemangioma", "Tattoos", "Scleroderma", "Burns" ], "interventions": [ { "name": "Optical Biopsy imaging", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 113, "start_date": "1999-06", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 1, "location_summary": "Irvine, California", "locations": [ { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00540566" }, { "nct_id": "NCT04596033", "title": "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Small-cell Lung Cancer", "Cutaneous Squamous Cell Carcinoma", "Anal Squamous Cell Carcinoma", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "GEN-011", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-11-11", "completion_date": "2022-06-27", "has_results": false, "last_update_posted_date": "2022-07-15", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04596033" }, { "nct_id": "NCT04869137", "title": "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Merkel Cell Carcinoma", "Neuroendocrine Carcinoma of the Skin", "Trabecular Carcinoma of the Skin" ], "interventions": [ { "name": "Lenvatinib Oral Product", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-05-28", "completion_date": "2026-09", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04869137" }, { "nct_id": "NCT00003549", "title": "S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma of the Skin" ], "interventions": [ { "name": "CMF regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "1998-10", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2012-10-08", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 84, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003549" }, { "nct_id": "NCT00002947", "title": "Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Langerhans Cell Histiocytosis", "Gastrointestinal Carcinoid Tumor", "Head and Neck Cancer", "Intraocular Melanoma", "Islet Cell Tumor", "Kidney Cancer", "Lung Cancer", "Melanoma (Skin)", "Neoplastic Syndrome", "Neuroendocrine Carcinoma of the Skin", "Pheochromocytoma" ], "interventions": [ { "name": "indium In 111 pentetreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "1996-10", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2014-07-02", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002947" }, { "nct_id": "NCT06223659", "title": "EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Merkel Cell Carcinoma", "Skin Squamous Cell Carcinoma" ], "interventions": [ { "name": "Eutectic Mixture of Local Anesthetics", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 100, "start_date": "2023-12-19", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06223659" }, { "nct_id": "NCT03538028", "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Microsatellite Instability (MSI)-High Endometrial Cancer", "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma (Uveal Melanoma Excluded)", "Merkel Cell Carcinoma", "Mesothelioma", "MSI-high Colorectal Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Small Cell Lung Cancer (SCLC)", "Renal Cell Carcinoma (RCC)", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "INCAGN02385", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-06-18", "completion_date": "2020-10-07", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 4, "location_summary": "Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538028" }, { "nct_id": "NCT05013099", "title": "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Merkel Cell Carcinoma, Unspecified", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "zirconium Zr 89 crefmirlimab berdoxam", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImaginAb, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2021-12-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013099" }, { "nct_id": "NCT04349436", "title": "Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Merkel Cell Carcinoma", "Basal Cell Carcinoma", "Locally Advanced Cutaneous Squamous Cell Carcinoma", "Cancer" ], "interventions": [ { "name": "RP1, intra-tumoral injection, oncolytic virus", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2020-05-15", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-07T21:33:37.584Z", "location_count": 24, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04349436" } ] }